Bonnie H. Anderson

Ms. Anderson is Chairman and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that leverages deep genomic insights to transform care at every step of the patient’s journey – from early detection to diagnosis to treatment decisions – in cancer and other diseases. Ms. Anderson’s career spans over 30 years in regulated diagnostics and life science markets. She cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She led Veracyte’s initial public offering in 2013, has spearheaded commercialization of its market-leading products and is now overseeing the company’s global expansion using its own distributed instrument platform.

Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the boards of Bruker Corporation and the Biotechnology Innovation Organization (BIO), and is President of the Coalition for 21st Century Medicine. She previously served on the board of Castle Biosciences and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson graduated from Indiana University of Pennsylvania with a Bachelor of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. She has received numerous awards for her industry leadership, including: the Wallace H. Coulter Award for Healthcare Innovation (2017); “Fiercest Women in Life Sciences” (FiercePharma 2017); “100 Most Creative People in Business” (Fast Company, 2015); “Most Influential Women in Bay Area Business” and “Bay Area’s Most Admired CEOs” (San Francisco Business Times, 2013 and 2014); and “Women of Influence” (Silicon Valley Business Journal, 2013). Under Ms. Anderson’s leadership, Veracyte has been named a “Top Workplace” by the Bay Area News Group, based solely on employee feedback, for seven consecutive years (2014-2020).